Standout Papers
Citation Impact
Citing Papers
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
ANCA and predicting relapse in systemic vasculitis
1995
Altered follicular regulatory T (Tfr)‐ and helper T (Tfh)‐cell subsets are associated with autoantibody levels in microscopic polyangiitis patients
2021
Leflunomide in Takayasu arteritis – A long term observational study
2016
Leflunomida na arterite de Takayasu – Estudo observacional de longo prazo
2016
Thrombosis in vasculitis: from pathogenesis to treatment
2015
Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study
1998
EULAR recommendations for the management of primary small and medium vessel vasculitis
2008 Standout
Hepatitis B Virus Infection — Natural History and Clinical Consequences
2004 Standout
Inflammation and cancer
2002 StandoutNature
A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
2003 Standout
Tissue production of pro-inflammatory cytokines (IL-1 , TNF and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis
2003
Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta‐analysis
2007
Pathogenetic Mechanisms of Septic Shock
1993 Standout
The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease
2016
10 Disease assessment and management of the vasculitides
1997
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
1995 Standout
Polyarteritis Nodosa and Extrahepatic Manifestations of HBV Infection: The Case Against Autoimmune Intervention in Pathogenesis
2001
Small-Vessel Vasculitis
1997 Standout
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab
2006
Renal revascularization in Takayasu arteritis–induced renal artery stenosis
2004
Prophylaxis of Pneumocystis Pneumonia in Immunocompromised Non-HIV-Infected Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials
2007
Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
2012
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients
2016
Pathogenesis and therapy of psoriasis
2007 StandoutNature
Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
2006
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener's granulomatosis
1997
Estrogen receptor α is a major mediator of 17β-estradiol’s atheroprotective effects on lesion size in Apoe–/– mice
2001 StandoutNobel
The Protective Effects of Estrogen on the Cardiovascular System
1999 Standout
Trial of Tocilizumab in Giant-Cell Arteritis
2017 Standout
Immune mechanisms in medium and large-vessel vasculitis
2013
Early and long-term results of subclavian angioplasty in aortoarteritis (takayasu disease): Comparison with atherosclerosis
1998
Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression.
1996
Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with wegener's granulomatosis
1994
Evidence‐based treatment of systemic vasculitis
2000
Anti-neutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential
1994
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial
2016
Stroke associated with giant cell arteritis: a population-based study
2014
Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia
2001
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
2002 Standout
Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic Disease
2002
Treatment of Antineutrophil Cytoplasm Autoantibody-Associated Systemic Vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group
1997
Development and Implementation of a Double‐Blind Corticosteroid‐Tapering Regimen for a Clinical Trial
2015
Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis
2007
Fc Receptors and Their Role in Immune Regulation and Autoimmunity
2005
IgG4-Related Disease
2012 Standout
Takayasu’s arteritis: Operative results and influence of disease activity
2006
Fibromuscular Dysplasia
2004 Standout
Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis
1995
Cancer and interstitial lung disease
2004
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
2008
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Cyclophosphamide in the Treatment of Idiopathic Pulmonary Fibrosis
2000
Inflammatory Bowel Disease
1991 Standout
Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.
1996
Clinical features of polymyalgia rheumatica and giant cell arteritis
2012
Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis
2010
Long‐term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re‐treatment
2006
Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody–associated vasculitis
2005
Glucocorticoids and invasive fungal infections
2003
Pulmonary and Oxygen Transport Effects of Intravenously Administered Endotoxin in Normal Humans
1992
Graves' Ophthalmopathy
2010 Standout
Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI)
1998
Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment
2006
Epidemiology of Takayasu arteritis
2017
Intracranial and Extracranial Neurovascular Manifestations of Takayasu Arteritis
2017
Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group
1996
The epidemiology of autoimmune diseases
2003
Conventional Therapy of Sjogren’s Syndrome
2007
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients
2000 Standout
Systemic Lupus Erythematosus
2011 Standout
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
2016
Malignant Gliomas in Adults
2008 Standout
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant‐cell arteritis
2002
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
1995 Standout
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis
2009
Takayasu arteritis: a review
2002
Differential B- and T-cell activation in Wegener’s granulomatosis
1999
Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis
1999
Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone
2014 StandoutNature
Therapy for the maintenance of remission in sixty‐five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole
1996
Estrogen plus Progestin and the Risk of Coronary Heart Disease
2003 Standout
Primary systemic vasculitis
1997
Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis
1998
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force
2007
Severe Adverse Cutaneous Reactions to Drugs
1994 Standout
Idiopathic Pulmonary Fibrosis
2001 Standout
Psoriasis
2003
Polymyalgia Rheumatica and Giant-Cell Arteritis
2002 Standout
Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity
2000
Trimethoprim–Sulfamethoxazole (Co-Trimoxazole) for the Prevention of Relapses of Wegener's Granulomatosis
1996
Hyperbaric-Oxygen Therapy
1996 Standout
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Production and Actions of Estrogens
2002 Standout
Pathogenesis of ANCA-associated systemic vasculitis
2000
IgG4‐related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases
2010
Atherosclerosis
2000 StandoutNature
Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides
1997
Infection in Solid-Organ Transplant Recipients
2007 Standout
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis
1998
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis
2007
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
2013 Standout
Incidence and predictors of large‐artery complication (aortic aneurysm, aortic dissection, and/or large‐artery stenosis) in patients with giant cell arteritis: A population‐based study over 50 years
2003 Standout
Anastomotic aneurysms after surgical treatment of Takayasu's arteritis: A 40-year experience
1998
Acute-Phase Proteins and Other Systemic Responses to Inflammation
1999 Standout
Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis
2016
Mycophenolate Mofetil for Maintenance Therapy of Wegener's Granulomatosis and Microscopic Polyangiitis
1999
B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions
2005
Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice
2002 StandoutNobel
Giant Cell Arteritis: Epidemiology, Diagnosis, and Management
2010
Perioperative Normothermia to Reduce the Incidence of Surgical-Wound Infection and Shorten Hospitalization
1996 Standout
Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups
2002
New Drugs for Rheumatoid Arthritis
2004
The value of pulse cyclophosphamide in ANCA‐associated vasculitis: meta‐analysis and critical review
2001
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
2003
Rituximab for Refractory Wegener's Granulomatosis
2005
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
The Biosynthesis of Collagen and Its Disorders
1979
Vessel-Specific Toll-Like Receptor Profiles in Human Medium and Large Arteries
2008
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
VASCULITIS IN CHILDREN AND ADOLESCENTS
1995
Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study
2001
Prevention of Infection Due toPneumocystisspp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients
2004
Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
1996
Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice
2002 StandoutNobel
T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission
1998
Estrogen Promotes Angiogenic Activity in Human Umbilical Vein Endothelial Cells In Vitro and in a Murine Model
1995
Abnormal Vascular Function and Hypertension in Mice Deficient in Estrogen Receptor β
2002 StandoutScienceNobel
Giant Cell Arteritis versus Takayasu Arteritis: An Update
2020
Estrogen-Receptor–Mediated Inhibition of Human Endothelial Cell Apoptosis
1997
Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves
2009 StandoutNobel
Effect of Postmenopausal Hormones on Inflammation-Sensitive Proteins
1999
Estrogen and Angiogenesis
2001
IgG4‐related systemic disease and lymphoplasmacytic aortitis
2009
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Granulomatous Vasculitis in Crohn’s Disease
1991
Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis
2009
POLYARTERITIS NODOSA, MICROSCOPIC POLYANGIITIS, AND CHURG-STRAUSS SYNDROME
1995
Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone
2001
Identification of Authentic Estrogen Receptor in Cultured Endothelial Cells
1996
The Syndrome of Lung Hemorrhage and Nephritis Is Usually an ANCA-Associated Condition
1996
Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
2009
Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment.
1995
Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b −/− Pdcd1 −/− mice
2005 StandoutNobel
Catalytic Asymmetric Transacetalization
2010 StandoutNobel
ESTROGENS AND ATHEROSCLEROSIS
1997
ANCA and associated diseases: immunodiagnostic and pathogenetic aspects
1993
Limitations of the 1990 American College of Rheumatology Classification Criteria in the Diagnosis of Vasculitis
1998
Direct Catalytic Asymmetric Synthesis of Cyclic Aminals from Aldehydes
2008 StandoutNobel
Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement.
1998
Incidence of Severe Infections and Infection‐Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double‐Cohort Study
2016
Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice
1999 StandoutNobel
Design of the Tocilizumab in Giant Cell Arteritis Trial
2013
Works of Gary S. Hoffman being referenced
Experience with surgical treatment of Takayasu's disease.
1991
Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study
2015
Large‐vessel vasculitis: Unresolved issues
2003
The clinical application of `edema-weighted' magnetic resonance imaging in the assessment of Takayasu's arteritis
1998
Takayasu arteritis: Utility and limitations of magnetic resonance imaging in diagnosis and treatment
2002
The treatment of wegener's granulomatosis with glucocorticoids and methotrexate
1992
A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score
2001
Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis
2012
Nomenclature of Systemic Vasculitides
1994 Standout
Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis
1996
Bronchoalveolar Lavage Analysis in Wegener's Granulomatosis: A Method to Study Disease Pathogenesis
1991
Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study
2011
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis
2006
Mediastinal mass and hilar adenopathy. Rare thoracic manifestations of wegener's granulomatosis
1997
Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
2005
Surrogate markers of disease activity in patients with Takayasu arteritis
1998
Wegener Granulomatosis: An Analysis of 158 Patients
1992 Standout
Substitution of Methotrexate for Cyclophosphamide in Wegener Granulomatosis
2007
Takayasu Arteritis and Giant Cell Arteritis
2009
The management of subglottic stenosis in patients with wegener's granulomatosis
1992
Interpretation of Head and Neck Biopsies in Wegenerʼs Granulomatosis
1990
Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases
2000
The uncertain role of immunosuppressive agents in Sjogren's syndrome
1997
Determinants of Vessel Targeting in Vasculitis
2005
Treatment of glucocorticoid‐resistant or relapsing takayasu arteritis with methotrexate
1994
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis
2011
Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patients
2007
Takayasu Arteritis: What is the Long-Term Prognosis?
2007
An analysis of forty‐two wegener's granulomatosis patients treated with methotrexate and prednisone
1995
The epidemiology of Wegener's granulomatosis. Estimates of the five‐year period prevalence, annual mortality, and geographic disease distribution from population‐based data sources
1996
Domains of health‐related quality of life important to patients with giant cell arteritis
2003
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis
2008
Antineutrophil cytoplasmic antibodies
1998
Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety
2001
Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1.
1994
Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: A comparison with Wegener's granulomatosis
2002
Limited Prognostic Value of Changes in Antineutrophil Cytoplasmic Antibody Titers in Patients with Wegener’s Granulomatosis
1993
METHOTREXATE USE IN SYSTEMIC VASCULITIS
1997
Herpes zoster in immunocompromised patients: Incidence, timing, and risk factors
2005
Recent advances in the medical management of Takayasu arteritis
2013
Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis
2007
Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with wegener's granulomatosis
1993
Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis
2004
ANCA Are Detectable in Nearly All Patients with Active Severe Wegener’s Granulomatosis
2007
Immunoglobulin G Antineutrophil Cytoplasmic Antibodies Are Produced in the Respiratory Tract of Patients with Wegener's Granulomatosis
1991
Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study
2005
Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide
1990
Pneumocystis carinii Pneumonia: A Major Complication of Immunosuppressive Therapy in Patients with Wegener's Granulomatosis
1995
Wegener granulomatosis in children and adolescents: Clinical presentation and outcome
1993
Analysis of FcgammaRII gene polymorphisms in Wegener's granulomatosis.
1997
DIFFERENTIATING THE VASCULITIDES
1994
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
2007
WEGENER'S GRANULOMATOSIS
1995
TREATMENT OF CORTICOSTEROID-RESISTANT GIANT CELL ARTERITIS
1995
Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation.
2003
Treatment of wegener's granulomatosis: Time to change the standard of care?
1997
Infectious complications complications of cyclophosphamide treatment for vasculitis
1989
Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital
1983
Etanercept combined with conventional treatment in Wegener's granulomatosis: A six‐month open‐label trial to evaluate safety
2001
Colchicine: Effects upon urinary hydroxyproline excretion in patients with scleroderma
1975
Therapy of resistant systemic necrotizing vasculitis. Polyarteritis, Churg-Strauss syndrome, Wegener's granulomatosis, and hypersensitivity vasculitis group disorders.
1995
The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event.
2007
THERAPY OF RESISTANT SYSTEMIC NECROTIZING VASCULITIS
1995
Takayasu Arteritis
1994 Standout
Longterm outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis.
2000